Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2015', provides an overview of the Vaginal Atrophy (Atrophic Vaginitis)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Vaginal Atrophy (Atrophic Vaginitis) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Vaginal Atrophy (Atrophic Vaginitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Vaginal Atrophy (Atrophic Vaginitis) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Vaginal Atrophy (Atrophic Vaginitis) Overview 7 Therapeutics Development 8 Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Overview 8 Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Comparative Analysis 9 Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics under Development by Companies 10 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Vaginal Atrophy (Atrophic Vaginitis) - Products under Development by Companies 14 Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development 15 Actavis plc 15 EndoCeutics, Inc. 16 Foamix Pharmaceuticals Ltd. 17 MediGene AG 18 Pantarhei Bioscience BV 19 Peptonic medical AB 20 RestorGenex Corporation 21 TherapeuticsMD Inc. 22 Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 esterol - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 estradiol hemihydrate - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 oxytocin - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 prasterone - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 RES-102 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 sinecatechins - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 TX-004HR - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 WC-3011 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Vaginal Atrophy (Atrophic Vaginitis) - Recent Pipeline Updates 44 Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects 46 Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones 47 Featured News & Press Releases 47 Mar 09, 2015: Physicians Visual Assessments Correlate with Objective Measurements of Postmenopausal VVA Patients Treated with TX-004HR VagiCap 47 Feb 20, 2015: Survey Shows Postmenopausal Women with VVA Reported Improved Satisfaction and Quality of Life with VagiCap Investigational Local Estrogen Treatment 47 Oct 28, 2014: First patients included in Peptonic Medical AB's clinical phase 2b study 48 Oct 15, 2014: TherapeuticsMD Announces Oral Presentation of Positive Phase 2 and Bioavailability Data on TX-004HR (VagiCap) 49 Sep 08, 2014: PEPTONIC Medical gets approvals to start the next clinical study 49 Jul 04, 2014: PEPTONIC Medical Progress Towards Next Clinical Study 50 Apr 07, 2014: Therapeutics MD Reports Positive Results of Rabbit Irritation Study for Its Estradiol Vaginal Capsule VagiCap (TX 004-HR) for Treatment of Vulvar Vaginal Atrophy 50 Jan 28, 2014: TherapeuticsMD Reports Positive PK Study Results for Its Estradiol Vaginal Capsule VagiCap (TX 12-004-HR) for Treatment of Vulvar Vaginal Atrophy 51 Oct 22, 2013: TherapeuticsMD Phase 1 Pilot Study Shows TX-12-004-HR Estradiol VagiCap Improves Conditions of Vulvar and Vaginal Atrophy 51 Aug 12, 2013: TherapeuticsMD commences Phase I study of vulvar and vaginal atrophy candidate 52 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2015 8 Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis) - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Actavis plc, H1 2015 15 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by EndoCeutics, Inc., H1 2015 16 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 17 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by MediGene AG, H1 2015 18 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Pantarhei Bioscience BV, H1 2015 19 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Peptonic medical AB, H1 2015 20 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by RestorGenex Corporation, H1 2015 21 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD Inc., H1 2015 22 Assessment by Monotherapy Products, H1 2015 23 Number of Products by Stage and Target, H1 2015 25 Number of Products by Stage and Mechanism of Action, H1 2015 27 Number of Products by Stage and Route of Administration, H1 2015 29 Number of Products by Stage and Molecule Type, H1 2015 31 Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Recent Pipeline Updates, H1 2015 44 Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H1 2015 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
